🌍·17h agoIndustry
Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma
Publisher
A
Allogene Therapeutics
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on allogene.com
Leave the platform to read the original full article on the publisher site.
Source: Allogene Therapeutics
Scope: Industry
Related coverage
More related coverage
Avacta Group·11h ago
Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform
Merck & Co. (MSD) News·6h ago
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Roche Newsroom·12h ago
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
Hyman, Phelps & McNamara (FDA Law)·13h ago